Breast Cancer Liquid Biopsy Market Size, Share, Trends, Report 2022-2030

The global breast cancer liquid biopsy market size was estimated at USD 87.71 million in 2021 and it is expected to hit around USD 368.75 million by 2030 with a moderate CAGR of 17.3% from 2022 to 2030.

Breast Cancer Liquid Biopsy Market Size 2021 to 2030

Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/39710

Breast cancer liquid biopsy market is growing as a result of the increasing prevalence of breast cancer among the population, growing awareness about early diagnosis, and treatment along with a rising preference for non-invasive procedures. For instance, according to WHO, in 2020, 2.3 million women were diagnosed with breast cancer which resulted in the death of 685,000 women globally. Moreover, liquid biopsy are been proposed as a novel method for early detection of breast cancer which further increases its adoption further propelling the growth.

Technological advancements in ongoing research on circulating biomarkers have led to the development of a lesser invasive method of detecting non-hematological cancers. Liquid biopsy is considered viable for real-time monitoring of patients in comparison with conventional tumor biopsy. Owing to continuous advancements in related areas, awareness about the clinical importance of liquid biopsy is growing. To make these technologies globally available, further interventional clinical trials are needed, along with the development of an algorithm to combine proper circulating biomarkers. Several companies are undertaking initiatives to boost the global adoption of biopsies which is contributing to growth. As per John Hopkins Medicine in June 2022, liquid biopsy can be used to detect advanced breast cancer biomarkers in 5 hours, commercialization of such tests in the upcoming years is projected to make the diagnosis of the condition easier.

North America dominated the overall market in 2021 which can be attributed to high disease prevalence, rapid technological advancements, and growing government initiatives for cancer diagnosis. The U.S. is the biggest market for liquid biopsy tests owing to a high prevalence rate of the condition in the country, there is significant usage of oncology diagnostic tests. Moreover, rapid technological advancements and recent FDA approvals for liquid biopsy tests coupled with intense competition between biotechnology companies are among the factors expected to boost market growth over the forecast period. Furthermore, major players operating in the region are focusing on collaboration and expansion to meet the escalating demand. For instance, in August 2022, Guardant and Merck KGaA collaborated to expand their precision therapeutics and focus on hard-to-treat cancer.

Scope of The Report

Report Coverage

Details

Market Size in 2021

USD 87.71 million  
 

Revenue Forecast by 2030

USD 368.75 million 

Growth rate from 2022 to 2030

CAGR of 17.3%
 

Base Year

2021

Forecast Period

2022 to 2030

Segmentation

Circulating Biomarkers, Application
 

Companies Covered

Biocept, Inc., Fluxion Biosciences, Inc., F. Hoffmann-La Roche Ltd., Sysmex Corporation, Thermo Fisher Scientific Inc. Menarini Group, NeoGenomics Laboratories, Inc., Qiagen N.V., and Myriad Genetics, I

 

Key Market Trends

The Circulating Cell-free DNA (cfDNA) Segment is Expected to Hold a Major Market Share

Circulating cell-free DNA (cfDNA) in plasma offers a non-invasive approach to monitor tumor molecular profiling in real-time at multiple time-points, detect emerging genomic alterations associated with drug resistance, and clarify cancer prognosis and diagnosis of cancer recurrence or progression. There are many companies that offer cfDNA-based products for use in research purposes. For example, Germany-based Qiagen offers the QIAamp circulating nucleic acid kit used in a column-based method to isolate cfDNA from plasma and serum. Genomics For Life Pty Ltd is a Queensland, Australia-based company that offers genetic testing for cfDNA from blood samples. It is a major private-sector company that provides cfDNA-based testing services in Australia.

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39710

According to the World Health Organization (WHO), in 2018, it was estimated that approximately 627,000 women died from breast cancer, which is nearly 15% of all cancer deaths among women globally. Due to technological advancements in breast cancer liquid biopsy, the circulating cell-free DNA segment is anticipated to show significant development. Bio-Rad Laboratories Inc. offers the 'QX200 Droplet Digital PCR (ddPCR)’ system, which provides absolute quantification of target DNA or RNA molecules for EvaGreen or probe-based digital PCR applications. In addition, the recent innovations leading to the introduction of better and more sensitive screening techniques (like ddPCR) have permitted the quantification and detection of low abundance targets in shorter times without requiring large numbers of replicates. This has established ddPCR as a tool of choice for liquid biopsies being utilized for breast cancer diagnosis. These developments are expected to fuel the market growth during the forecast period.

North America is Expected to Hold a Significant Share in the Market During the Forecast Period

The North American region is expected to hold a major share in the breast cancer liquid biopsy market. This is primarily due to the rising incidences of breast cancer and the growing demand for non-invasive treatment in this region.

According to the National Breast Cancer Foundation of the United States, in 2019, 62% of breast cancer cases were diagnosed at a localized stage. Female breast cancer represented approximately 15.2% of all new cancer cases in the United States. In the United States, Biocept, a molecular oncology diagnostics company, offers advanced methods for detecting circulating cancer cells (CTCs) and oncogene mutation fragments (ctDNA) in the blood. This allows CLIA-certified and CAP-accredited laboratories to perform predictive biomarker testing and provide the most up-to-date biomarker status from a non-invasive patient blood sample in breast cancer diagnosis, opening up opportunities in breast cancer liquid biopsy.

In July 2020, a group led by Canada-based Canexia Health launched a USD 1.9 million liquid biopsy screening initiative that aimed to improve access to testing and treatment options for Canadian cancer patients during the coronavirus pandemic. Initiatives like these are expected to affect the market development in a positive manner.

Furthermore, the high adoption rates of advanced diagnostic technologies such as PCR and NGS among healthcare professionals and the presence of well-established healthcare infrastructure are fueling the growth of the overall regional market to a large extent.

Key Players

  • Biocept, Inc.
  • Fluxion Biosciences, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc. Menarini Group 
  • NeoGenomics Laboratories, Inc.
  • Qiagen N.V.
  • Myriad Genetics, Inc.

Market Segmentation

  • By Circulating Biomarkers
    • Circulating Tumor Cells
    • Circulating Cell-free DNA
    • Extracellular Vesicles
    • Other Circulating Biomarkers
  • By Application
    • Targeting Treatment
    • Companion Diagnostics
    • Molecular
    • Others

Click Here to View Full Report Table of Contents

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39710

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://qyresearchmedical.com/

 

Back to news